Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

slno

Stock Based Compensation

Last Annual Value

45.85M

3-Year CAGR

163%

5-Year CAGR

98%

10-Year CAGR

47%

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Competitors Analysis of Stock Based Compensation

SLNO · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
45.85M
97.6%69.5%48.6% 
153.00M
4.2%7.8%12.2%
45.85M
31.9%21.2%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
21.38M
63.4%52.3%60.6%
33.94M
10.9%8.4%N/A
40.82M
34.6%46.3%36.7%
46.28M
96.5%N/AN/A
71.42M
26.8%25.3%N/A
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

Intrinsic Value
Current Price: $53.01